Please use this identifier to cite or link to this item:
Title: Surfing the pandemic wave: innovate or drown? A novel pharmacy model for COVID-19 oral therapy.
Author: Tabb, Jocelyn
Dimond, Renee
Bowen, Daniela
Dening, Kaitlin
Issue Date: 2022
Conference Name: Medicines Management 2022: The 46th SHPA National Conference
Conference Date: December 1-3
Conference Place: Brisbane
Abstract: Background: COVID-19 provided unprecedented global challenges to the delivery of health services, including the need for rapid implementation of innovative workflows to determine eligibility and safety of oral COVID-19 therapies. The model developed for ‘at home’ patients will be described. Objective: To provide a fully integrated, patient-centred, 7 day per week, multidisciplinary team approach to provision of oral COVID-19 therapies for patients isolating at home via National Medicines Stockpile (N) or Pharmaceutical Benefits Schedule (PBS) criteria. Action: Medical staff working remotely stratified patient eligibility for either Paxlovid (nirmatrelvir/ritonavir) or Lagevrio (molnupiravir) then referred onto the pharmacy service via Tea or email for comprehensive medication assessment. The pharmacy service included: telehealth consultation with the patient encompassing medication history interview; interaction checks; recommendations to the prescriber; patient counselling on the medication, interactions, recommended medication changes; documentation in patient’s electronic medical record, and follow-up from a pharmacist at the end of the treatment. Medication supply logistics were coordinated by the pharmacy technician. Evaluation: Over 2 months, 67 patients were referred to the pharmacy service, with 71% of pharmacist consultations occurring via telehealth. 63% of patients had a high complexity rating based on number of medicines and potential for interactions, and 93% of pharmacist recommendations were implemented. 82% of patients rated the service as excellent. The pharmacy service is an essential and valued step in the multidisciplinary model of care designed to provide optimal COVID-19 treatment at home. Discussion: The requirement to review medication histories and interactions before prescribing COVID-19 therapies, all remotely, forced the development of innovative models of interdisciplinary teamwork and patient interaction. The use of telehealth was integral in allowing provision of a model of care that was responsive, patient focused and effective. This model has the potential to be utilised in other areas of pharmacy practice.
Internal ID Number: 01972
Health Subject: COVID-19
Type: Conference
Appears in Collections:Research Output

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.